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In the past decade, the angiopoietin (ang)-1/2-Tie2 
system has increasingly been suggested to play a major 
role in the various features of human sepsis and acute 
lung injury and has thereby been considered as a novel 
therapeutic target [1-3]. High circulating ang-2 levels 
promote inﬂ  ammation and vascular permeability (in the 
lungs), while ang-1 has a protective eﬀ   ect, and these 
asso  ciations are conﬁ  rmed by clinical studies [4,5]. Th  e 
putative role of the ang-2/1 balance is gradually being 
expanded by studies showing that ang-2 levels may 
predict acute kidney injury and ICU outcome, even 
independently of disease severity [4,6].
In the current issue of Critical Care, Davis and colleagues 
[1] provide additional evidence that ang-2 release is 
associated with impaired vasoreactivity in patients with 
early sepsis, probably via interference with nitric oxide 
(NO), which can be considered as a pivotal patho  physio-
logic alteration in human sepsis. Th   ey measured vascular 
reactivity by the non-invasive reactive hyperemia-
peripheral artery tonometry (RH-PAT) technique, 
reviewed elsewhere [7]. Based on these observations, the 
authors conclude that ang-2 is a more meaningful 
biomarker of endothelial function in sepsis than 
‘currently used surrogate measures’, but formal evaluation 
of predictive values are lacking and the correlations are 
moderate at best. Also, the authors did not measure 
ang-1 levels, although the balance between ang-2 and 
ang-1 may determine the net biological eﬀ  ect. Finally, an 
inter  vention targeted at these molecules would be needed 
to reveal a direct role in microvascular responses in 
sepsis. Indeed, the angiopoietin-1/2-Tie2 system controls 
the responsiveness of the endothelium via multiple signal 
transduction pathways, including activation of Rho-like 
small GTPases, protein kinase C-zeta and Src [2,5], while 
the protein C system, a therapeutic target of alleged 
beneﬁ  t in human septic shock, may also be involved, as 
recently suggested [8]. Ang-1 may be associated with 
enhanced and ang-2 with decreased endothelial NO 
synthase and release, even clinically [9,10]. Conversely, 
changes in RH-PAT are but partly dependent on changes 
in NO levels [7]; we do not know this relationship in 
sepsis nor whether changes in the former are of prog-
nostic signiﬁ   cance for organ failure and mortality, so 
cannot be certain of their clinical signiﬁ  cance.
Cytokine-induced exocytosis by Weibel-Palade bodies 
of procoagulant factors as well as ang-2 is associated with 
downregulation of endothelial NO synthase and release 
[11,12]. Th  e NO and ang-2/1 balance may thus be 
inversely interrelated, both in control of synthesis in the 
endothelium as well as in pro-inﬂ  ammatory eﬀ  ects [10]. 
Hence, this may further explain the inverse relation (in 
time) between endothelial NO-dependent vascular reac-
tivity and circulating ang-2 in the study by Davis and 
colleagues [1]. Finally, vasopressin (V)2 receptors may 
contribute to exocytosis - a well known eﬀ  ect of selective 
V2 receptor-stimulating desmopressin and aselective 
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The interesting study by Davis and colleagues in 
the current issue of Critical Care expands on the 
increasingly recognized role of angiopoietins in human 
sepsis but raises a number of questions, which are 
discussed in this commentary. The authors describe 
an association between elevated angiopoietin (ang)-2 
levels and impaired vascular reactivity, measured by 
the partly nitric oxide-dependent fi  nger hyperemic 
response to forearm vascular occlusion, in patients with 
sepsis. This suggests that the ang-1/2-Tie2 system is 
involved in a number of pathophysiologic, phenotypic 
and perhaps prognostic alterations in human sepsis, 
on top of the eff  ect on pulmonary endothelial barrier 
function. The novel infl  ammatory route may be a 
target for future therapeutic studies in human sepsis 
and acute lung injury, including those with activated 
protein C.
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© 2010 BioMed Central LtdV1/2 receptor-stimulating vasopressin, for instance - but 
selective V1 receptor stimulation may antagonise it, as 
suggested by recent experimental work showing that the 
latter may reduce lung leakage and injury in a Gram-
positive ovine model of septic shock [13]. If that is the 
case, the excess mortality suggested by the trial on vaso-
pressin in the treatment of septic shock, at least when 
corticosteroids were not co-administered, can be ex-
plained, but ang-2 levels were not measured [14]. How-
ever, anti-inﬂ  ammatory eﬀ  ects of low dose vasopressin 
have also been observed but the role of the V1 receptor 
remains unclear [9,15]. Taken together, the control of 
Weibel-Palade bodies in sepsis deserves further study.
In conclusion, the study by Davis and colleagues [1] 
suggests that ang-2 plays a role in the pathogenesis of 
sepsis beyond its well-appreciated role in inﬂ  ammation 
and vascular permeability, by interfering with micro-
vascular control of blood ﬂ  ow. Th  e novel inﬂ  ammatory 
route may be a target for future therapeutic studies in 
human sepsis and acute lung injury, including those with 
activated protein C, V receptor agonists, statins and 
agents that improve endothelial NO.
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